Literature DB >> 15037584

Effect of metalloprotease inhibitors on corneal allograft survival.

Patrick M Stuart1, Fan Pan, Xiaotang Yin, Zdenka Haskova, Stacey Plambeck, Thomas A Ferguson.   

Abstract

PURPOSE: The expression of Fas ligand (FasL) in the cornea is essential for corneal allograft acceptance in mice. Because the expression of FasL on the surface of cells is sensitive to cleavage with matrix metalloproteases (MMPs), this study examined whether inhibitors of MMPs would lead to increased FasL expression and improved corneal allograft survival.
METHODS: Corneal endothelia derived from mice and humans were treated with MMP inhibitors, and FasL expression was examined. BALB/c mice were engrafted with C57BL/6 or C57BL/6-gld corneas and treated with an ointment containing the MMP inhibitor, doxycycline. Corneal allograft survival was monitored for 50 days.
RESULTS: Corneal endothelial cells from both mice and humans displayed increased surface expression of FasL after treatment with MMP inhibitors. The increase in surface expression was further evidenced by the ability of these cells to kill Fas-expressing target cells. Mice treated with doxycycline after corneal allograft transplantation showed significantly prolonged allograft survival and an increase in the overall acceptance rate.
CONCLUSIONS: MMP inhibitor treatment of cornea-derived endothelial cells results in increased FasL expression and function. MMP inhibitor treatment prolongs corneal allograft survival and results in a modest increase in corneal allograft acceptance.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15037584     DOI: 10.1167/iovs.03-0932

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  9 in total

Review 1.  Graft failure IV. Immunologic mechanisms of corneal transplant rejection.

Authors:  Eva-Marie Chong; M Reza Dana
Journal:  Int Ophthalmol       Date:  2008-06       Impact factor: 2.031

2.  Mice with mutations in Fas and Fas ligand demonstrate increased herpetic stromal keratitis following corneal infection with HSV-1.

Authors:  Jessica E Morris; Stephanie Zobell; Xiao-Tang Yin; Hamideh Zakeri; Bretton C Summers; David A Leib; Patrick M Stuart
Journal:  J Immunol       Date:  2011-12-07       Impact factor: 5.422

3.  Age-dependent changes in FasL (CD95L) modulate macrophage function in a model of age-related macular degeneration.

Authors:  Hui Zhao; Jayeeta Roychoudhury; Teresa A Doggett; Rajendra S Apte; Thomas A Ferguson
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-08-07       Impact factor: 4.799

4.  Targeting immune privilege to prevent pathogenic neovascularization.

Authors:  Jayeeta Roychoudhury; John M Herndon; Jiyi Yin; Rajendra S Apte; Thomas A Ferguson
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-02-17       Impact factor: 4.799

5.  Murine corneal transplantation: a model to study the most common form of solid organ transplantation.

Authors:  Xiao-Tang Yin; Deena A Tajfirouz; Patrick M Stuart
Journal:  J Vis Exp       Date:  2014-11-17       Impact factor: 1.355

6.  Feasibility study of lamellar keratoplasty in a murine model.

Authors:  Ting Huang; Stephen R Planck; James T Rosenbaum; Ellen J Lee
Journal:  Ocul Immunol Inflamm       Date:  2009 Jul-Aug       Impact factor: 3.070

7.  Therapeutic Use of Soluble Fas Ligand Ameliorates Acute and Recurrent Herpetic Stromal Keratitis in Mice.

Authors:  Megan Rogge; Xiao-Tang Yin; Lisa Godfrey; Priya Lakireddy; Chloe A Potter; Chelsea R Del Rosso; Patrick M Stuart
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-10       Impact factor: 4.799

8.  Doxycycline inhibits inflammation-induced lymphangiogenesis in mouse cornea by multiple mechanisms.

Authors:  Longhui Han; Wenru Su; Jingwen Huang; Jingwen Zhou; Sujuan Qiu; Dan Liang
Journal:  PLoS One       Date:  2014-09-30       Impact factor: 3.240

9.  Impaired Fas-Fas Ligand Interactions Result in Greater Recurrent Herpetic Stromal Keratitis in Mice.

Authors:  Xiao-Tang Yin; Tammie L Keadle; Jessicah Hard; John Herndon; Chloe A Potter; Chelsea R Del Rosso; Thomas A Ferguson; Patrick M Stuart
Journal:  J Immunol Res       Date:  2015-10-04       Impact factor: 4.818

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.